BlackRock, Inc. reports beneficial ownership of 7.6% of Amneal Pharmaceuticals, Inc. common stock, holding 24,121,119 shares as of 03/31/2026. The filing states these shares are attributed to certain "Reporting Business Units" of BlackRock, in accordance with SEC Release No. 34-39538 (January 12, 1998).
Positive
None.
Negative
None.
Insights
Large passive stake reported by BlackRock—common with asset managers.
BlackRock discloses beneficial ownership of 24,121,119 shares or 7.6% of Amneal as of 03/31/2026. The filing attributes holdings to specific Reporting Business Units rather than to a single business unit.
The position size is material in disclosure terms but represents a routine passive filing; subsequent trading activity will determine any market impact.
Filing follows Schedule 13G disclosure rules for large passive investors.
The schedule cites SEC Release No. 34-39538 and lists sole voting power of 23,876,182 shares and sole dispositive power of 24,121,119. The statement clarifies various persons may receive dividends or proceeds.
Any change in intent or active influence would trigger a different disclosure form; current filing signals passive reporting.
Key Figures
Beneficial ownership:24,121,119 sharesPercent of class:7.6%Sole voting power:23,876,182 shares+3 more
6 metrics
Beneficial ownership24,121,119 sharesAmount beneficially owned as reported
Percent of class7.6%Percent of Amneal common stock owned
Sole voting power23,876,182 sharesShares with sole power to vote
Sole dispositive power24,121,119 sharesShares with sole power to dispose
Reporting date03/31/2026Date tied to ownership figures on the cover page
Signature date04/27/2026Filing signed by Spencer Fleming, Managing Director
Key Terms
Schedule 13G, beneficially owned, sole dispositive power, Reporting Business Units
4 terms
Schedule 13Gregulatory
"Name of form and filing type on the cover"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially ownedfinancial
"reflects the securities beneficially owned, or deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive powerregulatory
"Sole power to dispose or to direct the disposition of: 24121119"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Reporting Business Unitsother
"beneficially owned by certain business units (collectively, the "Reporting Business Units")"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Amneal Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
03168L105
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
03168L105
1
Names of Reporting Persons
BlackRock, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
23,876,182.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
24,121,119.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
24,121,119.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
7.6 %
12
Type of Reporting Person (See Instructions)
HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Amneal Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
400 Crossing Blvd Bridgewater NJ 08807
Item 2.
(a)
Name of person filing:
BlackRock, Inc.
In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)
Address or principal business office or, if none, residence:
BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)
Citizenship:
See Item 4 of Cover Page
(d)
Title of class of securities:
Common Stock
(e)
CUSIP Number(s):
03168L105
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
24121119
(b)
Percent of class:
7.6 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
23876182
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
24121119
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Amneal Pharmaceuticals, Inc.. No one person's interest in the common stock of Amneal Pharmaceuticals, Inc. is more than five percent of the total outstanding common shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Exhibit 99
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
BlackRock reports beneficial ownership of 24,121,119 shares, representing 7.6% of Amneal common stock as of 03/31/2026. The shares are held by certain Reporting Business Units of BlackRock, per the filing.
Does BlackRock control voting of these Amneal shares?
The filing shows BlackRock has sole voting power over 23,876,182 shares and sole dispositive power over 24,121,119 shares. Shared voting and dispositive powers are reported as zero.
Is BlackRock identified as an active influencer of Amneal?
No change of intent is stated. The Schedule 13G filing cites passive reporting under SEC Release No. 34-39538, indicating the position is reported as passive rather than as an active control stake.
Who within BlackRock holds these Amneal shares?
The filing attributes the shares to certain "Reporting Business Units" of BlackRock, Inc.; it does not list individual business-unit holders by name and states it excludes holdings of other BlackRock units disaggregated under the cited release.
